91AV

Phishing warning 01-May-2024
We are aware of phishing emails targeting speakers of events whose names appear on our events pages. If you are unsure if an email regarding event registration or accommodation has come from us please contact us and do not provide any credit card details or personal information

The Astbury Conversation - Understanding Life in Molecular Detail

16 - 17 April 2018, Leeds, United Kingdom


Introduction
The Astbury Conversation is designed to give an insight into life in molecular detail - whether you are a researcher wanting to know about the latest developments, or you are simply interested in learning more about the hidden - but fascinating – world of macromolecules.

This event is inspired by the pioneering work at Leeds of the Braggs (Nobel prize 1913), and in the 1930s to 60s of Professor Bill Astbury, FRS, a field of research continued today in the Astbury Centre for Structural Molecular Biology.

It is fitting that more than 100 years after the Braggs’ Nobel Prize winning breakthrough we celebrate discoveries in structural molecular biology both within the University and across the wider scientific community by hosting the Astbury Conversation as one of the highlights of the University calendar.

The programme includes;
  • An academic Symposium themed around “Allostery in Biology” to include prestigious talks, selected presentations and poster sessions
  • Plenary Public Lecture by Nobel Laureate Professor Brian Kobilka of Stanford University,
  • A Public Engagement Event themed around “Understanding More about the Secret Life of Molecules”, followed by a wine reception.

Registrations for both the Academic Symposium and the Public Engagement Lecture and Event are now open.

Useful links

Speakers
  • Brian Kobilka MD, Prof of Molecular & Cellular Physiology, Stanford Uni., United States
  • Katrin Rittinger The Francis Crick Institute, London, United Kingdom
  • Professor Dame Carol Robinson Department of 91AV, University of Oxford, United Kingdom
  • Riki Eggert Randall Division of Cell and Molecular Biophysics, KCL, United Kingdom
  • David Agard Macromolecular Structure Group, University of California, United States
  • Richard Bayliss The Astbury Centre for Structural Molecular Biology, United Kingdom
  • Hagan Bayley Department of 91AV, University of Oxford, United Kingdom
  • John Briggs MRC Laboratory of Molecular Biology, Cambridge, United Kingdom
  • Babis Kalodimos Department of Structural Biology, St Jude Childrens Hospital, United States
  • Jim Naismith Division of Structural Biology, University of Oxford, United Kingdom
  • Adam Nelson The Astbury Centre for Structural Biology, United Kingdom
  • Matthias Rief The Institute of Molecular and Cellular Biophysics, United States

Sponsorship & supporting organisations
MedImmune

MedImmune pioneers innovative research across key therapeutic areas including RIA, cardiovascular & metabolic disease, oncology, neuroscience, and more. We develop medicines for unmet medical needs worldwide. We’re an industry leader in personalized medicine – developing new products that may allow doctors to prescribe a specific, customized treatment for each patient’s individual needs. We are the global biologics research and development arm of our parent company AstraZeneca, a recognized global leader in biopharmaceutical research and development. By combining AstraZeneca’s worldwide presence with our distinct and unique culture, processes, and standards, we continue to solve global healthcare challenges, redefine science, deliver better medicines, and help people live longer, healthier lives.

UCB

UCB aspires to be the patient-centric global biopharma leader, making a difference to the lives of people living with severe diseases. UCB is a global biopharmaceutical company, with a focus on neurology and immunology. Looking ahead, we have a solid platform for continuous growth through 2022 with our core products Cimzia®, Vimpat® and Neupro® and Keppra®, and we are preparing the launches of our next wave of potential medicines to help patients with epilepsy, lupus and osteoporosis. At the same time, we are very excited about the progress in our early pipeline. The key element of our evolution is to focus on the delivery of increased patient value. There is no such thing as an “average patient”. We want to use all the tools, channels and scientific advances at our disposal to develop a better understanding of the various expressions of a disease and embed the real needs of specific patient populations in our science and innovation process. Rather than starting researching any new drug with the science alone, we want to better connect patients with science and science with patients. Better understanding the reality of patients living with neurological and immunological disorders will enable us to take a more holistic approach to care, ensuring that ultimately the right drug and the right care reaches the right patients in order for them to live the lives they choose.
Venue
University of Leeds

University of Leeds, University of Leeds, Leeds, LS29JT, United Kingdom

Organised by
The Astbury Centre for Structural Molecular Biology (ACSMB) is an interdisciplinary research centre of the University of Leeds.

ACSMB brings together over fifty academic staff from three faculties - biological sciences, physical sciences (chemistry and physics) and medicine - who share the common goal of understanding life in atomic detail.
Contact information
Search
 
 
Showing all upcoming events
Start Date
End Date
Location
Subject area
Event type

Advertisement
Spotlight


E-mail Enquiry
*
*
*
*